22nd Century Group, Inc.

22nd Century Group is a leading agricultural biotechnology company focused on improving health and wellness through plant science. Their primary focus is tobacco harm reduction, specifically developing reduced nicotine content (RNC) tobacco products. The company holds the first and only FDA MRTP authorization for a combustible cigarette, VLN®, which contains 95% less nicotine than traditional cigarettes.

22nd Century employs a unique platform of modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding, to deliver healthier solutions. They also create new, proprietary plants with select alkaloid, terpenoid, and flavonoid profiles for use in the life science and consumer products industries. This diverse approach positions them as a leader in the agricultural biotechnology space, driving innovation in both tobacco harm reduction and broader plant science applications.

22nd Century Group, Inc. is a leading agricultural biotechnology company dedicated to improving health and wellness through plant science. Their primary mission is to reduce the harm caused by smoking through the development and distribution of reduced nicotine content (RNC) tobacco cigarettes. The company also creates new, proprietary plants with select alkaloid, terpenoid, and flavonoid profiles for the life science and consumer products industries. Their groundbreaking work has resulted in the first FDA-authorized reduced nicotine content cigarette designed to help smokers reduce their intake, marking a significant step toward a healthier future.

22nd Century Group promotes a culture of innovation and dedication to improving public health through plant science. They emphasize research-driven solutions, prioritizing scientific evidence and data-driven decision making. Their work is underpinned by a commitment to ethical practices, environmental sustainability, and a focus on creating healthier alternatives in the tobacco, hemp/cannabis, and hops industries.